upsid opaqu time hit paus
button downgrad hold
downgrad buy hold new hold rate
reect view forward revenu expect lack upsid pace
newsow motiv enthusiasm total address market
thesi play tougher see number sentiment upsid next
prior buy thesi upsid number upsid sentiment
larg play report sale growth vs
guid year-start enjoy plenti posit newsow reimburs
progress popul sequenc popseq initi announc health
system integr pilot genom test think path number
sentiment upsid tougher go forward
guid look realist see driver call conserv
year-start sale growth guidanc ident
version see driver upsid conclus
genom england gel program headwind sequenc servic
within sequenc consum alreadi assum acceler
tumor prole acceler non-invas prenat test nipt
could event event within sequenc instrument
encourag new price strategi sp ow cell introduct
novaseq could convert remaind legaci hiseq instal base
think year endeavour necessari keep instrument sale stabl
within microarray consum demand moder meaning reect
labcorp lh neg pre-announce
guidanc point herein
newsow support enthusiasm could slow
one import piec newsow hope
presum mid-year fda approv bristol myer
applic immuno-oncolog combo treatment util tumor mutat
burden tmb predict biomark tmb measur requir
product believ event follow announc
today withdrawn fda applic leav american colleg
obstetrician gynecologist acog anticip favor endors
price jan usd
buy hold
price target risk prior valuat
methodolog lean revenu multipl
histor appropri period
beat number enthusiasm
hot believ
time anymor therefor
switch ebitda price-to-earnings multipl
new price target reect
blend ebitda price-to-earnings multipl
anchor histor averag
ebitda price-to-earnings multipl past
multipl past year
correspond valu
averag price-to-earnings multipl
averag two methodolog yield
target upsid risk includ faster
instrument adopt market expans
key diagnost market downsid
particularli clinic market
distribut gmt
deutsch bank seek busi compani cover research report thu investor
awar rm may conict interest could aect object report investor consid
report singl factor make invest decis disclosur analyst certif
ngs-enabl nipt readili identi sentiment catalyst
smoke gun check noth get increment excit
alway talk customers/partners/etc hear anyth
recent check consid alarm mix dierent
past year peopl cri overcapac uncertain
clinic util growing/expand oer said also hear
anyth get overli excit interest tidbit price
accord one check advanc typic annual april
consum price increas feb surprisingli meaning cut
price novaseq chip novaseq xp kit
updat model follow pre-announce week ago
sale modestli exceed expect miss compon
save instrument big beat forecast meaning
chang save phase quarterli stale street number
look egregi mis-model minor adjust surfac
though mask major surgeri underneath built plumb model
better isol clinic diagnost consum genom assumpt
model avail link note
follow tabl summar think key point
varianc model
figur varianc forecast vs
thought key categori
acog averag risk endors taken longer expect
expand payer coverag like lag acog guidanc stage
unitedhealthcar largest manag care compani
recent reiter stanc ngs-enabl nipt cover
increas use genet marker guid treatment irrespect
organ origin continu acceler growth recent fda-
approv vitrakvi target solid tumor genet marker
support caus
bristol-my squibb announc withdraw
applic opdivo plu yervoy treatment rst-line lung cancer
patient high tumor mutat burden score result gener
product dent hope upsid view howev
expect mid-year approv would motiv increas use tmb
biomark still happen probabl event
lh neg pre-announce underscor much
slower anticip demand holiday
season guidanc similarli ag caution consum
test market big driver growth
 product custi endors average risk nipt need payer updat like risk without fda-approv tmb pre-announce guid suggest sharp transit health usag like pre-announce guid suggest sharp decelerationng adopt middl inning growth impetu latter inningstot partial off-set continu strength research januari
genom england gel conclud plan sequenc
whole human genom year project major
sequenc work conduct england
aspir research sequenc plan begin oer whole
genom sequenc nation health servic nh
expect initi annual monetari commit nh routin
sequenc program could lower gel spend plan oer
whole genom sequenc pediatr cancer part feasibl
due small incid diseas case per year
vs whole genom sequenc gel nh also
plan oer sequenc adult suer certain rare diseas
hard treat cancer number unspeci sound
limit us
fanfar precis medicin initi us
budget whole human genom rst year
scal end needl move amount plan scale
program meaning depend cost reduct whole
novaseq instrument placement upsid driver
result past year sinc launch inde compani appear
slightli miss guidanc novaseq placement
place instrument compar target rang
matter show longer box placement
stori realli year consum servic
compris sale compani still legaci hiseq
custom convert novaseq convers year
enough drive growth instrument
period end expens net incom attribut non-control incom attribut dilut share share alreadi ex amort cash flowoper cash cash ep incl
period end asset equival st receiv expens current current equip intang asset asset liabil account portion long-term current debt less current long-term liabil stockhold januari
